arrow
C

Carla Montironi

pathology
H指数:18
被引数:3,213

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib

CTNNB1突变型肝母细胞瘤的有效治疗性靶向WNTinib

2025-12-010
OAAI
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis

内皮-间质转化:一种可靶向机制,参与肝硬化门静脉血栓形成

2025-10-010
PRE
Artificial intelligence predicts outcome-related molecular profiles and vascular invasion in hepatocellular carcinoma

人工智能预测肝细胞癌的结局相关分子谱和血管侵犯

2025-09-110
OAAI
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC
2024-11-010
OAAI
Alcoholic Foamy Degeneration, an Entity Resembling Alcohol-Associated Hepatitis: Diagnosis, Prognosis, and Molecular Profiling
2024-04-010
OAAI
Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis

添加炎症标志物和完善国家酒精滥用和酒精中毒研究所标准可提高酒精相关性肝炎的诊断准确性

2023-11-016
PRE
Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

Elafibranor通过ppar β/δ 上调EMT诱导剂S100A4

2023-11-016
OAAI
Therapeutic targeting of adipose tissue macrophages ameliorates liver fibrosis in non-alcoholic fatty liver disease
2023-10-017
OAAI
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
2023-02-106
OA
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis (vol 75, pg 865, 2021)

非酒精性脂肪性肝炎患者肝细胞癌的分子特征 (vol 75,pg 865,2021)

2021-12-012
OA